Literature DB >> 1726165

Antibody prevalence of parenterally transmitted viruses (HIV-1, HTLV-I, HBV, HCV) in Austrian intravenous drug users.

J Pont1, C Neuwald, G Salzner.   

Abstract

UNLABELLED: From 1985 to 1990 the sera of 372 newly imprisoned intravenous drug users (IDU) were tested for HIV-1 antibodies. The seroprevalence was 18%, males 16% and females 31%. HIV-1 seroprevalence in Austrian IDU has not increased since 1986. All sera tested for HTLV-I-antibodies were negative. The majority of the HIV-1 seropositive drug users had been infected before 1985. The reported frequency of needle sharing has decreased since 1986. Of 151 IDU tested for HCV antibodies 75% were positive for anti-HCV, 68% were positive for hepatitis B markers, 59% were positive for both HBV and HCV markers, and 13% were positive for HIV-1 antibodies. IN
CONCLUSION: in Austrian IDU HCV seems to be the most frequent parenterally transmitted virus; HIV-1 seroprevalence has not increased since 1986; HLTV-I infection has not yet begun.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1726165     DOI: 10.1007/bf01726455

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  13 in total

1.  [AIDS and drug addicts in the view of an epidemiologist].

Authors:  B Velimirovic
Journal:  AIDS Forsch       Date:  1987-06

2.  [Increase in the prevalence of antibodies against LAV/HTLV III in drug addicts in West Germany].

Authors:  G Zoulek; L Gürtler; J Eberle; B Lorbeer; F Deinhardt
Journal:  Dtsch Med Wochenschr       Date:  1986-04-11       Impact factor: 0.628

3.  No evidence of HTLV-I infection in intravenous drug abusers in West Germany.

Authors:  A Krämer; J J Goedert; W A Blattner; U Marcus
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1988

4.  HTLV-I and HIV infection in drug addicts in Italy.

Authors:  A Gradilone; M Zani; G Barillari; M Modesti; A M Agliano; G Maiorano; L Ortona; L Frati; V Manzari
Journal:  Lancet       Date:  1986-09-27       Impact factor: 79.321

5.  HTLV-III antibodies in drug addicts in Spain.

Authors:  J M Rodrigo; M A Serra; E Aguilar; J A del Olmo; V Gimeno; L Aparisi
Journal:  Lancet       Date:  1985-07-20       Impact factor: 79.321

6.  HTLV-III antibody among Italian drug addicts.

Authors:  P Ferroni; D Geroldi; C Galli; A R Zanetti; A Cargnel
Journal:  Lancet       Date:  1985-07-06       Impact factor: 79.321

7.  HTLV-III antibody in Swiss and English intravenous drug abusers.

Authors:  P P Mortimer; E M Vandervelde; W J Jesson; M S Pereira; F Burkhardt
Journal:  Lancet       Date:  1985-08-24       Impact factor: 79.321

8.  [HTLV-III serology, epidemiology and clinical aspects of imprisoned i.v. drug-dependent males in Austria].

Authors:  J Pont; C Neuwald; C Kunz; W Werdenich
Journal:  Wien Klin Wochenschr       Date:  1986-07-18       Impact factor: 1.704

9.  An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis.

Authors:  G Kuo; Q L Choo; H J Alter; G L Gitnick; A G Redeker; R H Purcell; T Miyamura; J L Dienstag; M J Alter; C E Stevens
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

10.  Mutliple hepatitis viruses in multiple attacks of acute viral hepatitis.

Authors:  J W Mosley; A G Redeker; S M Feinstone; R H Purcell
Journal:  N Engl J Med       Date:  1977-01-13       Impact factor: 91.245

View more
  3 in total

1.  Prevalence and Clinical Impact of Human Pegivirus-1 Infection in HIV-1-Infected Individuals in Yunnan, China.

Authors:  Zhijiang Miao; Li Gao; Yindi Song; Ming Yang; Mi Zhang; Jincheng Lou; Yue Zhao; Xicheng Wang; Yue Feng; Xingqi Dong; Xueshan Xia
Journal:  Viruses       Date:  2017-02-15       Impact factor: 5.048

2.  HIV infection and risk factors among Bangkok prisoners, Thailand: a prospective cohort study.

Authors:  Hansa Thaisri; John Lerwitworapong; Suthon Vongsheree; Pathom Sawanpanyalert; Chanchai Chadbanchachai; Archawin Rojanawiwat; Wichuda Kongpromsook; Wiroj Paungtubtim; Pongnuwat Sri-ngam; Rachaneekorn Jaisue
Journal:  BMC Infect Dis       Date:  2003-10-28       Impact factor: 3.090

3.  Characterization of a Novel Hepatitis C Subtype, 6xj, and Its Consequences for Direct-Acting Antiviral Treatment in Yunnan, China.

Authors:  Yuanyuan Jia; Wei Yue; Qinghua Gao; Rui Tao; Yaxiang Zhang; Xiaoyang Fu; Yang Liu; Li Liu; Yue Feng; Xueshan Xia
Journal:  Microbiol Spectr       Date:  2021-08-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.